Eisai and Biogen begin application process for second Alzheimer's drug

Lecanemab, which is being developed as a treatment for Alzheimer's disease by Eisai and Biogen, has been sent to the FDA through a "rolling submission" process under an accelerated approval pathway.
Photo: BRIAN SNYDER/REUTERS / X90051
Photo: BRIAN SNYDER/REUTERS / X90051
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

Eisai and Biogen are now making another attempt to tackle Alzheimer's disease, initiating a "rolling submission" process at the US Food and Drug Administration (FDA) of the drug lecanemab, the companies inform in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading